- Trastuzumab therapy duration in HER2-positive de novo metastatic breast cancer: 1999–2018
Henry G. Kaplan et al, 2022, Breast Cancer Research and Treatment CrossRef - A Case Report on Prolonged Response with Trastuzumab Emtansine (T-DM1) in Recurrent Advance Breast Cancer Setting
Praneet Singh Bedi et al, 2023, Journal of Cancer Research Updates CrossRef - Crosstalk between HER2 and PD-1/PD-L1 in Breast Cancer: From Clinical Applications to Mathematical Models
Regina Padmanabhan et al, 2020, Cancers CrossRef